

### Michael Bookman Boston, MA



Michael serves as the Chief Legal Officer of Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company, a position he has served in since July 2021. Prior to joining Immuneering, Michael served as General Counsel and Secretary of Frequency Therapeutics (Nasdaq: FREQ) from September 2019 to July 2021. In this role, he served as a member of the Executive Leadership Team and established and led Frequency's Legal Department as its first in-house attorney. He also played a key role in Frequency's initial public offering in October 2019. Prior to his time at Frequency, Michael was an associate at Latham & Watkins LLP, a leading international law firm where he worked on corporate transactional, securities and general business and governance matters, with an emphasis on representing high-growth technology and life sciences companies. Michael holds a JD from the University of Virginia School of Law and a BBA, summa cum laude, from the University of Miami.